Therefore, the combinatorial treatment of triple-negative breast cancers with FGFR and AKT inhibitors may target two distinct signaling pathways that drive SOX10 expression by blocking both the induction and activation of Sox9. Here, SOX9 is linked to triple-negative breast carcinoma.